Phio Pharmaceuticals announces SMC recommendation to escalate to third dose cohort in PH-762 Phase 1b trial

Phio Pharmaceuticals Corp.

Safety Monitoring Committee reviewed safety data from second dose cohort and recommended escalation to next dose concentration.
First two patients in second cohort showed complete response (100% tumor clearance) and partial response (90% clearance) at Day 36.
No dose-limiting toxicities or serious adverse events reported in participants receiving intratumoral PH-762.
PH-762 is being studied for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma in Phase 1b trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.